Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature

Hepatology

Volumn 37, Issue 6, 2003, Pages 1309-1319

  Mommeja Marin, Herve ^a   Mondou, Elsa ^b   Blum, M Robert ^b   Rousseau, Franck ^b  

^a Division of Organic Chemistry   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PREDNISONE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL TRIAL; CORRELATION ANALYSIS; CROSS LINKING; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG POTENCY; GENOTYPE; HEPATITIS B; HUMAN; LIVER HISTOLOGY; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0038276960     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50208     Document Type: Review

References (50)

1. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcome of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759-768.
2. Lau DT-Y, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long term follow up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-1667.
3. Lok ASF, McMahon BJ. Chronic hepatitis B. AASLD practice guidelines. HEPATOLOGY 2001;34:1225-1241.
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;334:495-500.
5. Lee WM. Medical progress: hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
6. Evans AA, O'Connell AP, Pugh JC, Mason WS, Shen FM, Chen GC, Lin WY, et al. Geographic variation in viral load among hepatitis B carriers with differing risk of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998;7:559-565.
7. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
8. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, Fuschi P, et al. The long tetm course of chronic hepatitis B. HEPATOLOGY 1999;30:257-264.
9. Gerken G, Gomes J, Lampertico P, Colombo M, Rothaat T, Trippler M, Colucci G. Clinical evaluation and applications of the amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods 1998;74:155-165.
10. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decreamer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 2001;34:785-791.
11. De Man RA, Marcellin P, Habal F, Desmond P, Wright T, Rose T, Jurewicz R, et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. HEPATOLOGY 2000;32:413-417.
12. Lindh M, Hannoun C, Horal P, Krogsgaard K, and the intetpred study group. Virological response to interferon therapy of chronic hepatitis B as measured by a highly sensitive assay. J Viral Hepat 2001;8:349-357.
13. Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Yamashiro T, Maeshito T, Kinjo F, et al. Correlation between serum transaminase activity and virus load among patients with chronic liver disease type B. Hepatol Res 2001;21:159-168.
14. De Man RA, Wolters LMM, Nevens F, Chua D, Sherman M, Lai CL, Gadano A, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. HEPATOLOGY 2001;34:578-582.
15. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-313.
16. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of antiHBe positive chronic hepatitis B in alphainterferon treated and untreated patients: a long term cohort study. J Hepatol 2002;36:263-270.
17. Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. HEPATOLOGY 1999;29:277-282.
18. Hwang SJ, Lu RH, Wang YH, Chu CW, Wu JC, Chang FY, Lee SD. Clinical significance of changes in serum hepatitis B virus DNA titer in patients with chronic hepatitis B treated with interferon. Chung Hua I Hsueh Tsa Chih (Taipei) 2000;63:1-7.
19. Lin S-M, Sheen I-S, Chien R-N, Chu C-M, Liaw Y-F. Long term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. HEPATOLOGY 1999;29:971-975.
20. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen Helmer, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European concerted action on viral hepatitis (EUROHEP). HEPATOLOGY 1999;30:238-243.
21. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, et al. A randomized, controlled trial of 24-month course of interferon-alfa 2b in patients with chronic hepatitis B who had hepatitis B DNA without hepatitis B e antigen in serum. HEPATOLOGY 1997;26:1621-1625.
22. Lau DT-Y, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, et al. Long term therapy of hepatitis B with lamivudine. HEPATOLOGY 2000;32:828-834.
23. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
24. Leung NWY, Lai C-L, Chang T-T, Guan R, Lee C-M, Ng K-Y, Lim S-G, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rate: results after 3 years of therapy. HEPATOLOGY 2001;33:1527-1532.
25. Dienstag JL, Schiff ER, Wright TL, Perillo RP, Hann H-WL, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
26. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000;7:258-267.
27. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, Panella C, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001;35:805-810.
28. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002;36:543-546.
29. Zollner B, Schafer P, Feucht H-H, Schroter M, Petersen J, Laufs R. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001;65:659-663.
30. Sarin SK, Guptan RC, Thakut V, Malhotra S, Malhotra V, Banerjee K, Khandekar P. Efficacy of low dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: randomized controlled trial. J Hepatol 1996;24:391-396.
31. Yao FY, Tetrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. HEPATOLOGY 2001;34:411-416.
32. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, Bruno M, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001;35:406-411.
33. Schalm SW, Heathcote J, Cianciara J, Sherman M, Willems B, Dhillon A, Moorat A, et al. Lamivudine and alpha interferon combination treatments of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
34. Quint WGV, Heijtink RA, Schirm J, Gerlich WH, Niesters HGM. Reliability of methods for hepatitis B virus DNA detection. J Clin Microbiol 1995;33:225-228.
35. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R, and the Eurohep Pathobiology Group. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. J Clin Microbiol 1999;37:68-73.
36. Niesters HGM, Krajden M, Cork L, de Medina M, Hill M, Fries E, Osterhaus ADME. A multicenter study evaluation of the Digene hybrid capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of Eurohep standards. J Clin Microbiol 2000;38:2150-2155.
37. Pawlotsky JM, Bastie A, Hezode C, Lonjon I, Darthuy F, Remire J, Dhumeaux D. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods 2000;85:11-21.
38. Yates S, Penning M, Goudsmit J, Frantzen I, van der Weijer B, van Strijp D, van Gemen B. Quantitative detection of hepatitis B virus DNA by real-time nucleic acid sequence-based amplification with molecular beacon detection. J Clin Microbiol 2001;39:3656-3665.
39. Noborg U, Gusdal A, Pisa EK, Hedrum A, Lindh M. Automated quantification analysis of hepatitis B virus DNA by using the cobas amplicor HBV monitor test. J Clin Microbiol 1999;37:2793-2797.
40. Kao JH, Wood M, Chen PJ, Lai MY, Chen DS. Comparison of two methods for quantification of hepatitis B viral DNA. J Gastroenterol Hepatol 1999;14:423-426.
41. Gruber F, Falkner FG, Dorner F, Hammerle T. Quantification of viral DNA by real time PCR applying duplex amplification, internal standardization and two color fluorescence detection. Appl Environ Microbiol 2001;67:2837-2839.
42. Pas SD, Fries E, De Man RA, Osterhaus ADME, Niesters HGM. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000;38:2897-2901.
43. Marin IJ, Poljak M, Seme K, Meglic-Volkar J, Maticic M, Lesnicar G, Brinovec V. Comparative evaluation of semiautomated cobas amplicor hepatitis B virus (HBV) monitor test and manual microwell plate-based amplicor HBV monitor test. J Clin Microbiol 2001;39:758-761.
44. Saldanha J, Gerlich W, Lelie N, Dawson P, Heerman K, Heath A, the WHO Collaborative Study. An international collaborative study to establish a world health organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71.
45. Zavaglia C, Mondazzi L, Maggi G, Iamoni G, Gelosa F, Bellati G, Colloredo G, et al. Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B? Liver 1997;17:83-87.
46. Nair S, Perillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV-DNA dependent on levels of pretreatment viremia? HEPATOLOGY 2001;34;1021-1026.
47. Nagata I, Colucci G, Gregorio GV, Cheeseman P, Williams R, Mieli-Vergani G, Vergani D. The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B virus infection. J Hepatol 1999;30:965-969.
48. Lok AS, Ghany MG, Waston G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998;5:171-178.
49. Lau GKK, Tsiang M, Hou J, Yuen S-T, Carman WF, Zhang L, Gibbs CS, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. HEPATOLOGY 2000;32:394-399.
50. J Gauthier, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD. Quantification of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762.